Welcome visitor Log In - or - Register
0 items /
View Cart
Check Out
four ways
Quick Search:
AVL-292 (Spebrutinib)
B-cell antigen receptor (BCR) signaling is required for tumor expansion and proliferation. Bruton's Tyrosine Kinase (BTK) is an essential element of the BCR signaling pathway, playing an important role in B lymphocyte development, activation, signaling, proliferation and survival. Inhibiting BTK blocks BCR signaling and is of therapeutic significance in the treatment of both of B cell-related hematological cancers (e.g. non-Hodgkin lymphoma (NHL) and B cell chronic lymphocytic leukemia (B-CLL), and autoimmune diseases (e.g. rheumatoid arthritis). AVL-292 is a potent, selective and orally bioavailable irreversible inhibitor of BTK with IC50 value at low nM, currently in clinical trials.
Catalog NO: CT-AVL292
Synonym: Spebrutinib, CC-292
CAS NO: 1202757-89-8
Mol. Formula: C22H22FN5O3
MW: 423
** A white crystalline solid, >98.5% by HPLC + clean 1H-NMR, + a perfect quantitative elemental analysis. Ship within 1 day.